London, UK – 21 May 2026 - GHO Capital Partners Advisory Ltd, Europe's leading specialist healthcare investor, today highlighted FotoFinder Systems GmbH at its annual Investor Day, recognising the company's growing role in addressing one of the fastest-rising cancers worldwide.
The FotoFinder Group – including both the FotoFinder and DermLite brands – today presented its dermoscopy, Automated Total Body Mapping (ATBM), and AI-powered diagnostic technologies to more than 200 of GHO’s investors against a backdrop of accelerating demand for earlier, more accurate skin cancer detection. Melanoma is now the UK's 5th most common cancer, with incidence rates rising more than two-and-a-half times over the last 30 years, according to Cancer Research UK. During Skin Cancer Awareness Month in May, the NHS is again urging the public to check their skin and seek medical advice on suspicious or changing moles.
"FotoFinder exemplifies the healthcare innovation GHO is built to back - clinically validated, technologically advanced, and genuinely improving patient outcomes," said Ken Eichmann, Partner at GHO Capital. "As skin cancer awareness rises and health systems prioritise prevention, FotoFinder is uniquely placed to give clinicians the diagnostic confidence they need."
In the UK, FotoFinder and DermLite products are embedded in NHS dermatology pathways through the company's long-standing partnership with Schuco International (London) Ltd., supporting clinicians with imaging and diagnostic tools aligned to NHS priorities on earlier diagnosis and digital transformation.
"Our mission has always been to equip physicians with technology that detects skin cancer earlier and more accurately," said Tammy Noll, CEO of FotoFinder Systems GmbH. "The momentum behind skin health awareness shows just how vital this work is. With GHO Capital and partners like Schuco, we're advancing solutions that fit seamlessly into clinical workflows - and ultimately save lives."
About GHO Capital Partners Advisory Ltd
GHO Capital Partners Advisory Ltd. ("GHO"), is a leading specialist healthcare investment firm headquartered in London. GHO applies global capabilities and perspectives to unlock high-growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market-leading businesses of strategic global value. With c.€9 billion in assets under management, GHO partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster and more accessible healthcare.